Matthew White
Director of Finance/CFO at APIAM ANIMAL HEALTH LIMITED
Net worth: 34 294 $ as of 2024-03-30
Profile
Matthew White is currently the Chief Financial Officer at Apiam Animal Health Ltd.
since 2015.
Prior to this, he worked as a Finance Director at Merck Sharp & Dohme (Australia) Pty Ltd.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
APIAM ANIMAL HEALTH LTD.
0.08% | 2023-06-29 | 146,017 ( 0.08% ) | 34 294 $ | 2024-03-30 |
Matthew White active positions
| Companies | Position | Start |
|---|---|---|
| APIAM ANIMAL HEALTH LIMITED | Director of Finance/CFO | 2015-07-31 |
Former positions of Matthew White
| Companies | Position | End |
|---|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
 Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The private company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Director of Finance/CFO | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| APIAM ANIMAL HEALTH LIMITED | Distribution Services |
| Private companies | 1 |
|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The private company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Health Technology |
- Stock Market
- Insiders
- Matthew White
